Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 1

Идиопатический легочный фиброз: далеки ли мы от решения проблемы?
А.А. Визель, А.С. Белевский, И.Ю. Визель

References

1. Russian Respiratory Society. Idiopathic pulmonary fibrosis. Clinical guidelines. Moscow, 2017. 44 p. Available from: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ Accessed 2019 Jun 07. (In Russian).
2. Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF): an overview. Journal of Clinical Medicine 2018 Aug;7(8). pii: E201. doi: 10.3390/jcm7080201.
3. Wakwaya Y, Brown KK. Idiopathic pulmonary fibrosis: epidemiology, diagnosis and outcomes. The American Journal of the Medical Sciences 2019 May;357(5):359-69.
4. Hewitt RJ, Maher TM. Idiopathic pulmonary fibrosis: new and emerging treatment options. Drugs & Aging 2019 Jun;36(6):485-92.
5. Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respiratory Investigation 2018 Jul;56(4):268-91.
6. Pedraza-Serrano F, Jiménez-García R, López-de-Andrés A, Hernández-Barrera V, Sánchez-Muñoz G, Puente-Maestu L, de-Miguel-Díez J. Characteristics and outcomes of patients hospitalized with interstitial lung diseases in Spain, 2014 to 2015. Medicine (Baltimore) 2019 May;98(21):e15779.
7. Sköld CM, Arnheim-Dahlström L, Bartley K, Janson C, Kirchgaessler KU, Levine A, Ferrara G. Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015. Respiratory Medicine 2019 Aug;155:72-8.
8. Navaratnam V, Hubbard RB. The mortality burden of idiopathic pulmonary fibrosis in the United Kingdom. American Journal of Respiratory and Critical Care Medicine 2019 Jul 15;200(2):256-8.
9. Bolotova EV, Shulzhenko LV, Porkhanov VA, Raybova IN, Makrushina NI. A follow-up of patients with idiopathic pulmonary fibrosis. Russian Pulmonology 2018;28(1):37-42 (In Russian).
10. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society; Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine 2018 Sep;198(5):e44-68.
11. Graovac B. Idiopathic diffuse progressive interstitial pulmonary fibrosis (Hamman–Rich syndrome). Tuberkuloza 1967 Jan-Apr;19(1):94-104.
12. Ilkovich MM. Idiopathic fibrosing alveolitis. In: Disseminated lung diseases. Putov NV, editor. Moscow: Meditsina; 1984: 83-105. (In Russian).
13. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. The European Respiratory Journal 2011 Apr;37(4):743-6.
14. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 2011 Mar;183(6):788-824.
15. Casan Clarà P, Martínez González C, Ancochea J. Lung function testing in idiopathic pulmonary fibrosis: More than just spirometry? Archivos de Bronconeumología 2016 Sep;52(9):457-8.
16. Song H, Sun D, Ban C, Liu Y, Zhu M, Ye Q, Yan W, Ren Y, Dai H. Independent clinical factors relevant to prognosis of patients with idiopathic pulmonary fibrosis. Medical Science Monitor 2019 Jun;25:4193-201.
17. Shmelev EI. Idiopathic pulmonary fibrosis: from diagnosis to treatment. Consilium Medicum 2018;20(3):30-4 (In Russian).
18. Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU. Diagnostic likelihood thresholds that define a working diagnosis of idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2019 Jun 26. doi: 10.1164/rccm.201903-0493OC. [Epub ahead of print].
19. Fernández-Fabrellas E, Molina-Molina M, Soriano JB, Portal JAR, Ancochea J, Valenzuela C, Xaubet A; SEPAR-IPF National Registry. Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. Respiratory Research 2019 Jun;20(1):127.
20. Avdeyev SN, Trushenko NV. Antifibrotic therapy of idiopathic pulmonary fibrosis: efficacy/safety ratio. Medical Council 2018;15:131-6 (In Russian).
21. Liu F, Bayliss G, Zhuang S. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases. Clinical Science (London, England: 1979) 2019 Jun;133(12):1309-20.
22. Kawamura K, Ichikado K, Ichiyasu H, Anan K, Yasuda Y, Suga M, Sakagami T. Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience. BMC Pulmonary Medicine 2019 Jun;19(1):113.
23. Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Hallowell R, Jouneau S, Kondoh Y, Morrow L, Randerath W, Strek M, Tabaj G. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European Respiratory Review 2018 Dec;27(150). pii: 180074.
24. Jin J, Togo S, Kadoya K, Tulafu M, Namba Y, Iwai M, Watanabe J, Nagahama K, Okabe T, Hidayat M, Kodama Y, Kitamura H, Ogura T, Kitamura N, Ikeo K, Sasaki S, Tominaga S, Takahashi K. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1. Respiratory Research 2019 Jun;20(1):119.
25. Pleasants R, Tighe RM. Management of idiopathic pulmonary fibrosis. Annals of Pharmacotherapy 2019 Jul 7:1060028019862497. doi: 10.1177/1060028019862497. [Epub ahead of print].
26. Lima-Posada I, Fontana F, Pérez-Villalva R, Berman-Parks N, Bobadilla NA. Pirfenidone prevents acute kidney injury in the rat. BMC Nephrology 2019 May;20(1):158.
27. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. The Lancet 2011 May;377(9779):1760-9.
28. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine 2014 May;370(22):2083-92.
29. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2005 May;171(9):1040-7.
30. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. The European Respiratory Journal 2010 Apr;35(4):821-9.
31. Glassberg MK, Wijsenbeek MS, Gilberg F, Petzinger U, Kirchgaessler KU, Albera C. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. The European Respiratory Journal 2019 Jun 4. pii: 1900399. doi: 10.1183/13993003.00399-2019. [Epub ahead of print].
32. Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2017 Sep;196(6):756-61.
33. Ley B, Raj R, Trzaskoma B, Morgenthien E, Stauffer J, Limb S, Swigris J. The effect of season on hospitalization and mortality in patients with idiopathic pulmonary fibrosis treated with pirfenidone versus placebo. American Journal of Respiratory and Critical Care Medicine 2018;197:A4526.
34. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016 May;71(5):429-35.
35. Corral M, Reddy S, Chang E, Broder M, Gokhale S, Raimundo A. Rates of adherence and persistence of antifibrotic therapies in the US medicare population. American Thoracic Society 2019 International Conference. B103 ILD: Therapy / RAPid: Rapid Abstract Discussion Session; Monday, May 20, 2019. American Journal of Respiratory and Critical Care Medicine 2019;199:A4094.
36. Lee SH, Yeo Y, Kim TH, Lee HL, Lee JH, Park YB, Park JS, Kim YH, Song JW, Jhun BW, Kim HJ, Park J, Uh ST, Kim YW, Kim DS, Park MS; Korean Interstitial Lung Diseases Study Group. Korean guidelines for diagnosis and management of interstitial lung diseases: Part 2. Idiopathic pulmonary fibrosis. Tuberculosis and Respiratory Diseases (Seoul) 2019 Apr;82(2):102-17.
37. Dartsch RC, Fink L, Breithecker A, Markart P, Tello S, Seeger W, Günther A. Chronic fibrosing lung diseases: idiopathic pulmonary fibrosis from the perspective of its differential diagnosis. Der Internist 2019 Apr;60(4):345-61.
38. Molina-Molina M. The future of pharmacological treatment in idiopathic pulmonary fibrosis. Archivos de Bronconeumologia 2019 Jun 25. pii: S0300-2896(19)30260-1. doi: 10.1016/j.arbres.2019.05.008. [Epub ahead of print].
39. Clay E, Cristeau O, Chafaie R, Pinta A, Mazaleyrat B, Cottin V. Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France. Journal of Market Access and Health Policy 2019 Jun;7(1):1626171.
40. Stepanyan IE, Zaytseva AS, Shergina EA., Dmitriyeva LI, Degtyareva SA. Prolonged pirfenidone treatment in patients with idiopathic pulmonary fibrosis. Clinical Pharmacology and Therapy 2018;27(4):77-80 (In Russian).
41. Wu C, Lin H, Zhang X. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3). International Immunopharmacology 2019 Jun 19;74:105700.
42. Goobie GC, Guler SA, Johannson KA, Fisher JH, Ryerson CJ. YouTube videos as a source of misinformation on idiopathic pulmonary fibrosis. Annals of the American Thoracic Society 2019 May;16(5):572-9.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]